Amvis Holdings reports strong 2025 results, shifts focus for 2026

Amvis Holdings reported fiscal year 2025 financial results, achieving revenue of JPY 49.174 billion and EBITDA of JPY 8.966 billion. These figures exceeded revised full-year forecasts by 100.2% and 100.7%, respectively. Despite a challenging second half due to lower occupancy rates in facilities, the company maintained stable operations. EBITDA margin for the period was 18.2%, an 11.1 percentage point decrease from the previous year.

For fiscal year 2026, Amvis Holdings forecasts revenue of JPY 51.700 billion and EBITDA of JPY 7.100 billion, with an EBITDA margin of 13.7%. This outlook anticipates growth in its comprehensive medical support business, projected to generate JPY 850 million in revenue with a 70.6% margin. The company plans to open 9 new facilities in 2026, primarily in the Tokyo metropolitan area and Eastern Japan.

Amvis Holdings is shifting its investment strategy towards free cash flow and capital efficiency, while maintaining a strong financial foundation with an equity ratio well above its 30% target. The company aims to expand its comprehensive medical support business by increasing partnerships with medical institutions, offering consulting, financial support, and medical-nursing supplies.